Home/Medikine/Joseph Leveque, MD

JL

Joseph Leveque, MD

CEO, President, and Board Member

Therapeutic Areas

Oncology Autoimmune Disorders Infectious Disease

Medikine Pipeline

Drug	Indication	Phase
MDK-703	Immuno-oncology (T-cell modulation)	Preclinical

Leadership Team at Medikine

Marcos Milla, PhD

Chairman of the Board and Interim CSO

William J. Dower, PhD

Michael C. Needels, PhD

Ronald W. Barrett, PhD

View full Medikine profile